AB Sciex Q-Trap 5500 LC/MS/MS

AB Sciex Q-Trap 5500 LC/MS/MS

• 批准号: 7793254
• 负责人: Jennifer E Van Eyk
• 金额: $ 49.87万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-08 至 2011-04-07
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7793254
• 关键词: Address; Antibodies; Biological Assay; Biological Markers; Biology; Blood Vessels; Cardiology; Clinical; Clinical Medicine; Cystic Fibrosis; Data Analyses; Data Quality; Development; Diabetes Mellitus; Ensure; Enzyme-Linked Immunosorbent Assay; Equipment; Funding; HIV; Human; Laboratories; Liquid substance; Malignant Neoplasms; Proteins; Proteome; Request for Proposals; Research Personnel; Sampling; Sickle Cell Anemia; Stroke; System; Time; Work; assay development; cohort; experience; instrument; mass spectrometer; multiple reaction monitoring; nano; numb protein; public health relevance; translational study

DESCRIPTION (provided by applicant): This proposal requests funds for an Applied Biosystems SCIEX QTRAP 5500 mass spectrometer with an Ultra 2D nano liquid chromatographic (LC) system from Eksigent, This system has been chosen specifically for the clinical/translational studies in which absolute quantification of a single or many proteins is obtained using an approach known as multiple reaction monitoring (MRM). MRM assays produce the same quality data as a ELISA but without the need for antibodies. Thus, MRM condenses the time and expense of quantitative assay development for one or more protein in clinical sample sets. Furthermore, multiplex MRM assays eliminate the need for antibody arrays, which are technically challenging and often limited. We will be using the QTRAP 5500 LC/MS/MS specifically for MRM assays in the context of large clinical cohorts where the unique aspects of this equipment are essential. Examples include situations where (i) a large number of proteins (40+), and their modified forms are assayed simultaneously, (ii) maximal sensitivity is needed for broad proteome coverage (1e7+), (iii) large sample sets (500+) must be examined and (iv) only very small quantities of irreplaceable samples are available. A group of very experienced investigators with targeted studies to address key clinical questions will use the QTRAP 5500. Seven teams constitute the major users and include researchers and MS experts from the Johns Hopkins CTSA/ITCR Biomarker Development Center directed by Jennifer Van Eyk, and the laboratories of Anne Murphy, Allen Everett and James Casella, Josef Coresh, M. Christine Zink and David Graham, Harry (Hal) Dietz as well as Gerald Hart. The researchers will work collaboratively to maximize the instrument use and to ensure high quality and effective data analysis. The projects address clinical questions in cardiology, vascular biology, stroke, diabetes, sickle cell anemia, cystic fibrosis, cancer, and HIV. Each project is poised to impact clinical medicine. PUBLIC HEALTH RELEVANCE: This proposal requests funds for a mass spectrometer capable of quantifying specific proteins in clinical samples. The unique aspects of this particular instrument is it's (i) ability to simultaneously analyze a large number of proteins and their modified forms (40+), (ii) increased sensitivity which maximizes proteome coverage (1e7+), (iii) capability to analyze large sample numbers (500+) with (iv) very small quantities of human clinical samples. The projects address important and pressing clinical questions in cardiology, vascular biology, stroke, diabetes, sickle cell anemia, cystic fibrosis, cancer, and HIV. Each project is poised to impact clinical medicine.

描述（由申请人提供）：该提案要求使用Eksigent的超2D Nano液态色谱（LC）系统进行应用的生物系统Sciex QTRAP 5500质谱仪，该系统已专门为临床/翻译研究选择了该系统，该系统是使用单个或多次反应（使用多个蛋白质的绝对量化）的临床/翻译研究。 MRM分析产生与ELISA相同的质量数据，但不需要抗体。因此，MRM在临床样本集中将一种或多种蛋白质的定量测定开发的时间和费用凝结。此外，多重MRM分析消除了对抗体阵列的需求，抗体阵列在技术上具有挑战性且通常有限。我们将在大型临床队列中使用QTRAP 5500 LC/MS/MS专门用于MRM分析，在此设备的独特方面至关重要。示例包括（i）（i）大量蛋白质（40+）及其修改的形式同时进行测定，（ii）广泛的蛋白质组覆盖范围（1E7+），（iii）仅需检查大量蛋白质组（1E7+）即可进行最大敏感性（500+），并且仅检查非常小的irreplaceples。一群经验丰富的研究人员进行有针对性的研究来解决关键临床问题，将使用QTRAP5500。七个团队组成了主要用户，包括Johns Hopkins CTSA/ITCR生物标志物开发中心的研究人员和MS专家，由Jennifer van Eyk和Jennifer van Eyk和Jandert ander and ander and and and and and and and and and ander and and and and and and and and and and and and and and and and and and and and ander and ander an and and and and james coresh，杰克·塞恩（James Casell），杰克·塞恩（James Casell），以及杰拉尔德·哈特（Gerald Hart）。研究人员将共同努力以最大程度地利用仪器使用并确保高质量有效的数据分析。这些项目解决了心脏病学，血管生物学，中风，糖尿病，镰状细胞贫血，囊性纤维化，癌症和HIV中的临床问题。每个项目都准备影响临床医学。 公共卫生相关性：该提案要求资金用于质谱仪，能够量化临床样本中的特定蛋白质。该特定仪器的独特方面是（i）能够同时分析大量蛋白质及其修改形式的能力 （40+），（ii）提高灵敏度，从而最大程度地提高了蛋白质组覆盖率（1E7+），（iii）用（iv）非常少量的人类临床样品分析大型样本数（500+）的能力。这些项目解决了心脏病学，血管生物学，中风，糖尿病，镰状细胞贫血，囊性纤维化，癌症和HIV中重要的临床问题。每个项目都准备影响临床医学。